The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial An independent Data Monitoring Committee (DMC) completed a...Read more
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced...Read more
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients...Read more
Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the IMFINZI regimen vs. chemotherapy alone WILMINGTON, Del. / Nov 26, 2025 / Business Wire / AstraZeneca’s IMFINZI® (durvalumab)...Read more
Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to begin before the end of the year The enhanced immunosuppressive regimen is designed to mitigate the risk of acute liver injury (ALI) and acute liver...Read more
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 /PRNewswire/ --...Read more
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Praxis Precision Medicines | 8.02 4.25 | $196.56 |
| Movano Health | 7.39 237.62 | $10.50 |
| Belite Bio | 6.38 4.92 | $136.00 |
| ProMIS Neurosciences | 6.21 2,145.25 | $6.50 |
| Nutex Health | 6.20 5.50 | $119.00 |
| Alnylam Pharmaceuticals | 6.11 1.37 | $451.23 |
| Bright Minds Biosciences | 4.84 7.32 | $71.00 |
| Bolt Biotherapeutics | 4.58 819.50 | $5.14 |
| Insmed | 4.49 2.20 | $209.00 |
| Natera | 3.70 1.56 | $240.82 |
| Polyrizon | 2.75 526.44 | $3.27 |
| Establishment Labs | 2.66 3.91 | $70.67 |
| Ascendis Pharma | 2.32 1.10 | $212.33 |
| Verrica Pharmaceuticals | 2.15 32.04 | $8.86 |
| Sol-Gel Technologies | 1.87 4.60 | $42.56 |
| BrainsWay | 1.66 10.49 | $17.49 |
| Illumina | 1.64 1.26 | $131.45 |
| Apogee Therapeutics | 1.58 2.24 | $71.97 |
| Company | Volume | Last Trade |
|---|---|---|
| Pasithea Therapeutics | 441,347,031 | $1.27 |
| HeartBeam | 322,782,653 | $0.74 |
| Aditxt | 62,332,011 | $3.44 |
| ImmunityBio | 43,720,143 | $2.39 |
| OneMedNet | 43,492,349 | $1.71 |
| Pfizer | 15,500,613 | $25.77 |
| Microbot Medical | 14,808,804 | $2.48 |
| Novo Nordisk | 14,140,945 | $49.40 |
| Zynex | 13,633,645 | $1.21 |
| Savara | 13,366,864 | $6.18 |
| Recursion | 12,537,888 | $4.61 |
| iSpecimen | 12,465,104 | $0.42 |
| Clearmind Medicine | 11,752,345 | $0.15 |
| Reviva Pharmaceuticals | 11,654,411 | $0.56 |
| Kala Bio | 11,059,914 | $0.97 |
| Applied Therapeutics | 10,538,309 | $0.26 |
| Incannex Healthcare | 8,371,312 | $0.36 |
| CureVac | 7,692,843 | $5.47 |
| AbCellera Biologics | 7,472,630 | $3.78 |
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
